Search Result

Results for "

HER

" in MedChemExpress (MCE) Product Catalog:

By Targets:	EGFR (151) ADC Antibody (3) ADC Cytotoxin (3) ADC Linker (1) Akt (10) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (10) Apoptosis (32) Autophagy (20) Bacterial (3) Bcl-2 Family (1) Biochemical Assay Reagents (1) BRK (1) Btk (3) c-Met/HGFR (7) Caspase (1) CDK (18) COX (1) Dihydrofolate reductase (DHFR) (3) Drug-Linker Conjugates for ADC (6) Epigenetic Reader Domain (1) ERK (3) Estrogen Receptor/ERR (8) Fatty Acid Synthase (FASN) (2) HDAC (1) HSP (13) IGF-1R (1) Interleukin Related (1) Isotope-Labeled Compounds (5) Itk (1) JAK (1) JNK (1) Ligands for Target Protein for PROTAC (1) Mitochondrial Metabolism (1) MMP (2) Monoamine Oxidase (2) mTOR (1) Necroptosis (1) NF-κB (1) NO Synthase (1) p38 MAPK (5) PARP (2) PD-1/PD-L1 (1) PDGFR (3) PI4K (1) Potassium Channel (1) PROTACs (5) Radionuclide-Drug Conjugates (RDCs) (4) Raf (1) Reactive Oxygen Species (1) STING (1) Survivin (2) Thymidylate Synthase (2) TNF Receptor (2) Toll-like Receptor (TLR) (5) Topoisomerase (4) Trk Receptor (1) VEGFR (13) Virus Protease (2) Wnt (1)
By Research Areas:	Cancer (226) Cardiovascular Disease (1) Endocrinology (2) Infection (1) Inflammation/Immunology (14) Neurological Disease (1)
Click Chemistry:	TCO (1) Azide (1) Alkynes (1)
Oligonucleotides:	Antisense Oligonucleotides (2)

230

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: EGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-163419

HER2-IN-18	EGFR	Cancer
HER2-IN-18 is a *HER2* inhibitor, with an IC₅₀ less than 200 nM for HER-YVMA and HER-WT. HER2-IN-18 can be used for cancer research .

HY-143323

HER2-IN-9	EGFR	Cancer
HER2-IN-9 is an orally active *HER2* inhibitor, with an IC₅₀ value of 0.03 μM. HER2-IN-9 inhibits HER-2 positive breast cancer cells proliferation and migration. HER2-IN-9 can be used in the research of breast cancers .

HY-144097

HER2-IN-8	EGFR	Inflammation/Immunology Cancer
HER2-IN-8 is a *HER-2* inhibitor extracted from patent WO2021179274A1 compound 107. HER2-IN-8 can be used for the research of cancer and inflammation .

HY-151118

HER2-IN-11	Apoptosis	Cancer
HER2-IN-11 is a psoralen derivative. HER2-IN-11 has anti-breast cancer activity and light-activated cytotoxicity. HER2-IN-11 induces apoptosis .

HY-151116

HER2-IN-10	Apoptosis	Cancer
HER2-IN-10 is a psoralen derivative. HER2-IN-10 has anti-breast cancer activity and light-activated cytotoxicity. HER2-IN-10 induces apoptosis .

HY-151162

HER2-IN-12	EGFR	Cancer
HER2-IN-12 is a *HER2* inhibitor (IC₅₀: 121 nM). HER2-IN-12 can be used in the research of cancers, such as breast cancer .

HY-163417

HER2-IN-15	EGFR	Cancer
HER2-IN-15 (Compound 1) is an inhibitor for HER2, which inhibits the Her YVMA exon 20 insertion mutation (HER2 YVMA) with an IC₅₀ <200 nM. HER2-IN-15 inhibits proliferation of HER2 YVMA mutated BaF3 cells with an IC₅₀ <200 nM and amliorates non-small-cell lung cancer (NSCLC) .

HY-163418

HER2-IN-17	EGFR	Cancer
HER2-IN-17 (Compound 2) is an inhibitor for HER2, which inhibits the Her YVMA exon 20 insertion mutation (HER2 YVMA) with an IC₅₀ <200 nM. HER2-IN-17 inhibits proliferation of HER2 YVMA mutated BaF3 cells with an IC₅₀ <200 nM and amliorates non-small-cell lung cancer (NSCLC) .

HY-163420

HER2-IN-16	EGFR	Cancer
HER2-IN-16 (Compound 14) is an inhibitor for HER2, which inhibits the Her YVMA exon 20 insertion mutation (HER2 YVMA) with an IC₅₀ <200 nM. HER2-IN-16 inhibits proliferation of HER2 YVMA mutated BaF3 cells with an IC₅₀ <200 nM and amliorates non-small-cell lung cancer (NSCLC) .

HY-153557

HER2-IN-13	EGFR Potassium Channel	Cancer
HER2-IN-13 (Compound 33) is an *HER2* inhibitor with an IC₅₀ of 8 nM. HER2-IN-13 also inhibits wt-EGFR with an IC₅₀ of 0.40 μM .

HY-153557A

HER2-IN-14	EGFR	Cancer
HER2-IN-14 (Compound 34) is an *HER2* inhibitor with an IC₅₀ of 18 nM. HER2-IN-14 also inhibits wt-EGFR with an IC₅₀ of 6.3 μM .

HY-143734

HER2-IN-6	EGFR	Cancer
HER2-IN-6 is a potent inhibitor of *HER2. HER2-IN-6 has the potential for the research of wild and/or mutant EGFR and/or HER*2 kinase mediated tumor (extracted from patent WO2021164697A1, compound 11) .

HY-163657

HER2-IN-20	EGFR	Cancer
HER2-IN-20 (compound 32) is a potent and selective HER2 ^WT and HER2 ^YVMA inhibitor with IC₅₀ values of 49, 42 nM, respectively. HER2-IN-20 has the potential for the research of non-small cell lung cancer (NSCLC) .

HY-143733

HER2-IN-5	EGFR	Cancer
HER2-IN-5 is a potent and orally active *HER-2* inhibitor, example 10, extracted from patent WO2021164697 .

HY-143874

HER2-IN-7	EGFR	Cancer
HER2-IN-7 is a potent inhibitor of *HER2. Deregulation of ErbB family signalling modulates proliferation, invasion, metastasis, angiogenesis, and tumour cell survival. HER2-IN-7 has the potential for the research of diseases associated ErbBs (especially HER*2), including cancer (extracted from patent WO2019214634A1, compound 23) .

HY-163453

HER2-IN-19	EGFR	Cancer
HER2-IN-19 (Compound 10e) is a potent inhibitor of *HER2* and EGFR with IC₅₀ values of 0.87 respectively and 3.5 nM. HER2-IN-19 has potent inhibitory activity against tumor cells, IC₅₀ ^NCI-N87 = 1.63 nM, IC₅₀ ^BT474= 15.17 nM, IC₅₀ ^{BaF3-HER2YVMA} = 1.49 nM .

HY-P10648

Herceptide HER2-targeting peptide	EGFR	Cancer
Herceptide (HER2-targeting peptide) is a *HER2*-targeting peptide, and can be further conjugated to the near-infrared fluorescent dye indocyanine green (HY-D0711) (ICG) for developing theranostic agents .

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers .

HY-P99813

Patritumab deruxtecan HER3-DXd; U3-1402	Antibody-Drug Conjugates (ADCs)	Cancer
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .

HY-P4082

ErbB-2-binding peptide HER2-binding peptide	EGFR	Cancer
ErbB-2-binding peptide (HER2-binding peptide) is a tumor-binding peptide. ErbB-2-binding peptide has the potential for cancer research .

HY-110333

BMS-599626 dihydrochloride	EGFR	Cancer
BMS-599626 dihydrochloride is a small molecule *pan-HER* (human epidermal growth factor receptor) kinase inhibitor. BMS-599626 dihydrochloride primarily targets *HER1* (IC₅₀=20 nmol/L) and *HER2* (IC₅₀=30 nmol/L) kinase activity in the HER family. BMS-599626 inhibits the kinase activity of *HER1* and *HER2* by competing with their ATP-binding sites, and can inhibit the downstream signaling pathway by blocking the heterodimer formation of *HER1* and *HER2. BMS-599626 dihydrochloride can be used to study the antitumor effects of multiple HER1* or *HER2* overexpressed tumor models .

HY-P10569

*Biotin HER-2 substrate peptide*	EGFR	Cancer
Biotin HER-2 substrate peptide is a substrate of Her4 and Her2/neu tyrosine kinase with a K_m value of 60 μm for Her2/neu kinase domain .

HY-P9912A

*Pertuzumab (anti-HER2)*	EGFR	Cancer
Pertuzumab (anti-HER2), a humanized monoclonal antibody, is a *HER2* dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-144677

*pan-HER-IN-2*	EGFR Apoptosis	Cancer
pan-HER-IN-2 (Compound C6) is a reversible, orally active pan-HER inhibitor with IC₅₀ values of 0.72, 2.0, 8.2 and 75.1 nM against EGFR, *HER4, EGFR ^T790M/L858R* and *HER2, respectively. pan-HER-IN-2 induces apoptosis* and shows antitumor activities .

HY-144676

*pan-HER-IN-1*	EGFR Apoptosis	Cancer
pan-HER-IN-1 (Compound C5) is an irreversible, orally active pan-HER inhibitor with IC₅₀ values of 0.38, 1.6, 2.2 and 3.5 nM against EGFR, *HER4, EGFR ^T790M/L858R* and *HER2, respectively. pan-HER-IN-1 induces apoptosis* and shows antitumor activities .

HY-P9907A

*Trastuzumab (anti-HER2)* 25+ Cited Publications Anti-Human HER2, Humanized Antibody (PBS)	ADC Antibody EGFR	Cancer
Trastuzumab (PBS) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (PBS) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

HY-162623

*EGFR/HER2-IN-15*	EGFR	Cancer
EGFR/HER2-IN-15, a dihydropyrimidine, is a potent *EGFR/HER2* inhibitor. EGFR/HER2-IN-15 significantly inhibits EGFR ^wt activity with an IC₅₀ of 37.21 nM. EGFR/HER2-IN-15 has anticaner effects .

HY-157399

*EGFR/HER2-IN-10*	EGFR	Cancer
EGFR/HER2-IN-10 (compound 9F) is a potent and selective dual *EGFR/HER2* inhibitor with IC₅₀s of 2.3 nM and 234 nM for EGFR and HER2, respectively. EGFR/HER2-IN-10 shows an effective antiproliferative action against prostate carcinoma .

HY-153796

*PROTAC Her3 Degrader-8*	PROTACs	Cancer
PROTAC Her3 Degrader-8 (Compound PP2) is a PROTAC that can degrade Her3 protein in vitro and cell experiments, and can be used to study diseases regulated by HER family proteins .

HY-151161

*EGFR/HER2-IN-8*	EGFR	Cancer
EGFR/HER2-IN-8 (compound 34) is a *EGFR/HER2* and DHFR inhibitor. EGFR/HER2-IN-8 inhibits EGFR kinase, HER2 kinase and DHFR with IC₅₀s of 0.45, 0.244 and 5.669 μM, respectively. EGFR/HER2-IN-8 shows anticancer activity against several cancer cell lines with high safety profile and selectivity indices. EGFR/HER2-IN-8 can be used for the research of cancer .

HY-151156

*EGFR/HER2-IN-6*	EGFR Apoptosis	Cancer
EGFR/HER2-IN-6 (compound 43) is an *EGFR/HER2* and DHFR inhibitor. EGFR/HER2-IN-6 inhibits EGFR kinase, HER2 kinase and DHFR with IC₅₀s of 0.122, 0.078 and 0.585 μM, respectively. EGFR/HER2-IN-6 shows anticancer activity against several cancer cell lines with high safety profile and selectivity indices. EGFR/HER2-IN-8 can be used for the research of cancer .

HY-115951

*EGFR/HER2-IN-2*	EGFR	Cancer
EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual inhibitor of EGFR and *HER2* with IC₅₀ values of 5.02 µM and 0.83 µM against EGFR and HER2, respectively .

HY-115952

*EGFR/HER2-IN-3*	EGFR	Cancer
EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual inhibitor of EGFR and *HER2* .

HY-153111

*EGFR/HER2-IN-9*	EGFR	Cancer
EGFR/HER2-IN-9 (Compound 1) is an EGFR and *HER2* inhibitor with IC₅₀s of 3.2, 8.3 and 14 nM against EGFR, EGFR T790M and HER2, respectively .

HY-151158

*EGFR/HER2-IN-7*	EGFR	Cancer
EGFR/HER2-IN-7 is a potent anticancer agent with high selectivity against MCF-7 breast cancer cells. EGFR/HER2-IN-7 is a *EGFR/HER2* kinase and DHFR inhibitor, with IC₅₀s of 0.18 μM (EGFR), 0.146 μM (HER2), respectively. EGFR/HER2-IN-7 shows moderate inhibition on DHFR (IC₅₀=0.907 μM) .

HY-161602

*EGFR/HER2-IN-13*	EGFR	Cancer
EGFR/HER2-IN-13 (Compd 38) is an inhibitor of mutant EGFR/HER2s which are resistant to other drugs. EGFR/HER2-IN-13 can be used for cancer research .

HY-161603

*EGFR/HER2-IN-14*	EGFR	Cancer
EGFR/HER2-IN-14 (Compd 46) is an inhibitor of mutant EGFR/HER2s which are resistant to other drugs. EGFR/HER2-IN-14 can be used for cancer research .

HY-107444

*PROTAC Her3-binding moiety 1*	Ligands for Target Protein for PROTAC	Cancer
PROTAC HER3-binding moiety 1 (compound 1b) is a Her3 Ligand for PROTAC .

HY-160682

*EGFR/HER2-IN-12*	EGFR	Others
EGFR/HER2-IN-12 (compound 14b) is a dual inhibitor of EGFR and HER2 with 81% and 51% inhibition at 10 μM. The toxicity of EGFR/HER2-IN-12 to cancer cells A431 and MDA-MB-361 was not significant .

HY-159519

*EGFR/HER2-IN-16*	Apoptosis EGFR	Cancer
EGFR/HER2-IN-16 (compound 12K) is an effective dual-target inhibitor of EGFR (IC₅₀=6.15 nM) and *HER-2* (IC₅₀=9.78 nM) with anti-tumor activity. EGFR/HER2-IN-16 can inhibit the migration of SK-BR-3 cells, arrest the cell cycle in the G0/G1 phase, and induce apoptosis. EGFR/HER2-IN-16 exhibits good anti-proliferative activity against tumor cell models and has little damage to healthy cells. EGFR/HER2-IN-16 can be used in breast cancer research .

HY-146238

*EGFR/HER2/TS-IN-1*	EGFR Thymidylate Synthase Apoptosis	Cancer
EGFR/HER2/TS-IN-1 (Compound 4d) is an EGFR, *HER2* and TS (Thymidylate synthase) inhibitor with IC₅₀ values of 0.203, 0.088 and 0.168 μM against EGFR, HER2 and TS, respectively. EGFR/HER2/TS-IN-1 induces MCF7 cell apoptosis .

HY-P9907

Trastuzumab 25+ Cited Publications Anti-Human HER2, Humanized Antibody	Radionuclide-Drug Conjugates (RDCs) EGFR ADC Antibody	Cancer
Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

HY-160613

*EGFR/HER2-IN-11*	EGFR	Cancer
EGFR/HER2-IN-11 (compound 20) is an orally active dual inhibitor for human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), with IC₅₀s of 7.7 and 22 nM, respectively. EGFR/HER2-IN-11 exhibits antitumor efficacy and inhibits proliferation against cancer cells BT-474 with GI₅₀ of 601 nM .

HY-149633

*EGFR/HER2/DHFR-IN-3*	EGFR Dihydrofolate reductase (DHFR) Apoptosis	Cancer
EGFR/HER2/DHFR-IN-3 (compound 4c) is a potent dual inhibitor of *EGFR/HER2, with IC₅₀s of 0.138 and 0.092 μM, respectively. EGFR/HER2/DHFR-IN-3 also inhibits DHFR, with an IC₅₀* of 0.193 M. EGFR/HER2/DHFR-IN-3 causes arrest at the S phase of the cell cycle and induces apoptosis in MCF7 breast cancer cells .

HY-147992

*EGFR/HER2-IN-4*	EGFR	Cancer
EGFR/HER2-IN-4(compound 6d) is an orally active irreversible dual inhibitor. EGFR/HER2-IN-4 inhibits EGFR with an IC₅₀ value of 0.6 nM and demonstrates potent EGFR kinase inhibitory activities on L858R and T790M mutations. EGFR/HER2-IN-4 has potent antitumor efficacy in vivo and can be used for lung cancer research .

HY-147994

*EGFR/HER2-IN-5*	EGFR	Cancer
EGFR/HER2-IN-5 (compound 6h) is an orally active irreversible dual inhibitor. EGFR/HER2-IN-5 inhibits EGFR with an IC₅₀ value of 1.01 nM and demonstrates potent EGFR kinase inhibitory activities on L858R and T790M mutations. EGFR/HER2-IN-5 has potent antitumor efficacy in vivo and can be used for lung cancer research .

HY-151154

*EGFR/HER2/DHFR-IN-1*	EGFR	Cancer
EGFR/HER2/DHFR-IN-1 is a potent anticancer agent with high selectivity against MCF-7 breast cancer cells. EGFR/HER2/DHFR-IN-1 is a multiple inhibitor of *EGFR/HER2* kinase and DHFR, with IC₅₀s of 0.153 μM, 0.108 μM, 0.291 μM, respectively. EGFR/HER2/DHFR-IN-1 arrests cell cycle at G1/S and induces cells apoptosis .

HY-146239

*EGFR/HER2/TS-IN-2*	EGFR Thymidylate Synthase	Cancer
EGFR/HER2/TS-IN-2 (compound 17) is a potent *EGFR/HER2* and TS (Thymidylate synthase) inhibitor, with IC₅₀ values of 0.173, 0.125, and 1.12 μM, respectively. EGFR/HER2/TS-IN-2 shows cytotoxic activity against MDA-MB-231 cancer cell lines, with an IC₅₀ of 1.69 µM .

HY-147797

*EGFR/HER2/CDK9-IN-2*	EGFR CDK	Cancer
EGFR/HER2/CDK9-IN-2 (Compound 9) is a potent inhibitor of EGFR/HER2/CDK9 with IC₅₀*s of 145.35, 129.07, and 117.13 nM, respectively. EGFR/HER2/CDK9-IN-2 exhibits remarkable antitumor activity .*

HY-147798

*EGFR/HER2/CDK9-IN-3*	EGFR CDK	Cancer
EGFR/HER2/CDK9-IN-3 (Compound 10) is a potent inhibitor of EGFR/HER2/CDK9 with IC₅₀*s of 191.08, 132.65, and 113.98 nM, respectively. EGFR/HER2/CDK9-IN-3 exhibits remarkable antitumor activity .*

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P9907A

*Trastuzumab (anti-HER2)* Maximum Cited Publications 29 Publications Verification Anti-Human HER2, Humanized Antibody (PBS)	Classification of Application Fields Disease Research Fields Cancer	ADC Antibody EGFR
Trastuzumab (PBS) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (PBS) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

HY-P9907

Trastuzumab Maximum Cited Publications 29 Publications Verification Anti-Human HER2, Humanized Antibody	Classification of Application Fields Disease Research Fields Cancer	Radionuclide-Drug Conjugates (RDCs) EGFR ADC Antibody
Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

HY-P9912

Pertuzumab 5+ Cited Publications	Classification of Application Fields Disease Research Fields Cancer	EGFR
Pertuzumab, a humanized IgG1 monoclonal antibody, is a *HER2* dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-P99030

Margetuximab	Classification of Application Fields Disease Research Fields Cancer	EGFR
Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC₅₀ value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .

HY-P99605

Cinrebafusp alfa PRS 343	Classification of Application Fields Disease Research Fields Cancer	EGFR TNF Receptor
Cinrebafusp alfa (PRS 343) is a high affinity *CD137/HER2* bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (K_d=0.3 nM) and human monomeric CD137 (4-1BB; K_d=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research .

HY-P99507

Zenocutuzumab MCLA-128; PB4188; R040517	Classification of Application Fields Disease Research Fields Cancer	EGFR
Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of *HER2* and *HER3* .

HY-P99437

Anbenitamab KN-026	Classification of Application Fields Disease Research Fields Cancer	EGFR
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human *HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER*2-positive metastatic breast cancer (MBC) research .

HY-P99676

Izalontamab SI-B001	Classification of Application Fields Disease Research Fields Cancer	EGFR
Izalontamab (SI-B001) is a bispecific *anti-EGFR/HER3* monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .

HY-P99936

Elgemtumab LJM716	Classification of Application Fields Disease Research Fields Cancer	EGFR
Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential .

HY-P99630

Gancotamab MM-302	Classification of Application Fields Disease Research Fields Cancer	EGFR
Gancotamab (MM-302) is a *HER2*-targeted antibody-liposomal Doxorubicin conjugate with antitumor activity. Gancotamab encapsulates Doxorubicin to facilitate its delivery to HER2-overexpressing tumor cells .

HY-P9921A

Trastuzumab emtansine (solution) 2 Publications Verification Ado-Trastuzumab emtansine (solution) ; PRO132365 (solution) ; T-DM 1 (solution)	Classification of Application Fields Disease Research Fields Cancer	Antibody-Drug Conjugates (ADCs) EGFR
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer .

HY-P99896

Runimotamab	Classification of Application Fields Disease Research Fields Cancer	Others
Runimotamab is an IgG1-κ humanized chimeric antibody targeting CD3E and HER2 .

HY-P99275

Patritumab 1 Publications Verification Human Anti-ERBB3 Recombinant Antibody	Classification of Application Fields Disease Research Fields Cancer	EGFR Akt ERK PARP Survivin
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, *HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis* and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-10261B

(E/Z)-Afatinib (E/Z)-BIBW 2992	Classification of Application Fields Disease Research Fields Cancer	EGFR Apoptosis c-Met/HGFR Akt p38 MAPK Autophagy
(E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells .

HY-P99304

Lumretuzumab Anti-Human ERBB3 Recombinant Antibody	Classification of Application Fields Disease Research Fields Cancer	EGFR
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody that can be used for the research of cancer .

HY-P9974

Vantictumab OMP-18R5	Classification of Application Fields Disease Research Fields Cancer	Wnt
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .

HY-P99380

Zanidatamab ZW 25	Classification of Application Fields Disease Research Fields Cancer	EGFR
Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct *HER2* epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity .

HY-P99854

Disitamab RC48-0	Classification of Application Fields Disease Research Fields Cancer	EGFR ADC Antibody
Disitamab (RC48-0) is a humanized monoclonal antibody targeting *HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (Disitamab vedotin (HY-P9985)*) .

HY-N0289

Lycorine hydrochloride 10+ Cited Publications	Alkaloids Structural Classification Lycoris radiata (L’Her.) Herb. Pyrrole Alkaloids Classification of Application Fields Plants Isoquinoline Alkaloids Amaryllidaceae Inflammation/Immunology Disease Research Fields Cancer	Autophagy Bacterial Virus Protease
Lycorine hydrochloride is the main active ingredient of the herbal medicine derived from Lycoris radiata (L’Her.) Herb. and is also a melanoma vasculogenic inhibitor and has anti-tumor activity . Lycorine hydrochloride effectively inhibits mitotic proliferation of Hey1B cells (IC₅₀ of 1.2 μM) .

HY-30270

Mequinol p-Hydroxyanisole	Structural Classification Monophenols Classification of Application Fields Source classification Mercurialis Other Diseases Phenols Euphorbiaceae Plants Disease Research Fields	HSP Estrogen Receptor/ERR
Mequinol (4-Methoxyphenol)yes MercurialisOne of the bioactive ingredients, mainly used for skin discoloration . MequinolIs an antioxidant that has additive/synergistic effects on carcinogenesis when combined with other phenolic antioxidants. Mequinolalso promote hERαDependent chaperone production with potential estrogenic activity .

HY-N1986

Cucurbitacin D	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Cucurbitaceae Trichosanthes kirilowii Maxim. Plants Disease Research Fields Cancer	HSP
Cucurbitacin D is an active component in Trichosanthes kirilowii, disrupts interactions between Hsp90 and two co-chaperones, Cdc37 and p23. Cucurbitacin D prevents Hsp90 client (Her2, Raf, Cdk6, pAkt) maturation without induction of the heat shock response. Anti-cancer activity .

HY-P99268

Seribantumab SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody	Classification of Application Fields Disease Research Fields Cancer	EGFR Apoptosis
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets *HER3*. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .

HY-30270R

Mequinol (Standard)	Structural Classification Monophenols Source classification Mercurialis Phenols Euphorbiaceae Plants	HSP Estrogen Receptor/ERR
Mequinol (Standard) is the analytical standard of Mequinol. This product is intended for research and analytical applications. Mequinol (4-Methoxyphenol)yes MercurialisOne of the bioactive ingredients, mainly used for skin discoloration . MequinolIs an antioxidant that has additive/synergistic effects on carcinogenesis when combined with other phenolic antioxidants. Mequinolalso promote hERαDependent chaperone production with potential estrogenic activity .

HY-N0289R

Lycorine hydrochloride (Standard)	Alkaloids Structural Classification Lycoris radiata (L’Her.) Herb. Pyrrole Alkaloids Plants Isoquinoline Alkaloids Amaryllidaceae	Autophagy Bacterial Virus Protease
Lycorine (hydrochloride) (Standard) is the analytical standard of Lycorine (hydrochloride). This product is intended for research and analytical applications. Lycorine hydrochloride is the main active ingredient of the herbal medicine derived from Lycoris radiata (L’Her.) Herb. and is also a melanoma vasculogenic inhibitor and has anti-tumor activity . Lycorine hydrochloride effectively inhibits mitotic proliferation of Hey1B cells (IC50 of 1.2 μM) .

Cat. No.	Product Name	Chemical Structure

HY-13631DS

Dxd-d5
Dxd-d₅ is a deuterium labeled Dxd. Dxd is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a) [1].

HY-50767S

Palbociclib-d8
Palbociclib-d₈ is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].

HY-50767S1

Palbociclib-d4 hydrochloride
Palbociclib-d₄ (hydrochloride) is the deuterium labeled Palbociclib hydrochloride. Palbociclib (PD 0332991) is a selective CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].

HY-32721S

Neratinib-d6
Neratinib-d₆ (HKI-272-d6) is the deuterium labeled Neratinib. Neratinib (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor with IC50s of 59 nM and 92 nM for HER2 and EGFR, respectively.

HY-10261S1

Afatinib-d4
Afatinib-d₄ is the deuterium labeled Afatinib. Afatinib (BIBW 2992) is an irreversible EGFR family inhibitor with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively.

HY-10261AS

Afatinib-d6 dimaleate
Afatinib-d₆ (dimaleate) is the deuterium labeled Afatinib dimaleate. Afatinib dimaleate is an irreversible EGFR family inhibitor with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively[1][2].

HY-10260S1

Vandetanib-d4
Vandetanib-d₄ is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1][2].

HY-10260S

Vandetanib-d6
Vandetanib-d₆ is the deuterium labeled Vandetanib. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1].

HY-10260S2

Vandetanib-13C6
Vandetanib-13C6 is a deuterated labeled Vandetanib . Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC₅₀=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC₅₀=110 nM) and *EGFR/HER1* (IC₅₀=500 nM) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Species:	Human (51) Rhesus Macaque (10) Mouse (6) Rat (9) Cynomolgus (5) Canine (2)
Tag:	His (55) Tag Free (3) Strep (1) Avi (17) Myc (1) GST (6) Fc (21)
Source:	HEK293 (69) CHO (1) Sf9 insect cells (10) E. coli (1)


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

HER

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Natural
Products